Cantourage Group SE
NuWays RecommendationRecommendation
Buy
Price Target
€10.50
Upside
208.82%
Chart
- 1M
- 3M
- 6M
- YTD
- 1Y
- 3Y
€3.40
-€0.10 (-2.86%)
Realtime-Data from 23.09.2025 15:43:29
Cantourage Group SE, founded in Berlin in 2019, is reshaping the medical cannabis market. By uniting global cultivators' expertise with their own industry experience, they simplify import processes for licensed growers. Cantourage handles regulatory complexities, processing raw materials into EU-compliant end products sold through wholesalers and pharmacies. With a network spanning 50 suppliers from 15 countries, they offer a diverse range of high-quality products. In September 2023, Cantourage also launched its own telemedicine platform for medical cannabis, telecan°, to better benefit from Germany’s de-classification of cannabis as a narcotic drug in April 2024.
ISIN
DE000A3DSV01
Market Cap
€42.39M
Enterprise Value
€39.74M
26 week avg vol.
10820
Primar Exchange
Scale
IPO
2022
Sector
health-care-pharma
Headquarters
Berlin, DE
Employees
55
Incorporated
2019
CEO
Philip Schetter
Website
Free Float
28.40%
Patrick Hoffmann
22.10%
Florian Holzapfel
21.80%
PiFriva Verwaltungs- und Beteiligungs GmbH
15.80%
Think.Health Projekt M GmbH & Co. KG
11.90%
31.10.2025
Publication half yearly financial report
KPIs in EUR
KPI | 2024 | 2025e | 2026e |
---|---|---|---|
Sales | 51.42M | 88.62M | 105.41M |
EBITDA | 3.88M | 6.49M | 10.05M |
EBIT | -324.15K | 2.29M | 5.85M |
EPS | -0.02 | 0.13 | 0.33 |
FCF | 1.63M | 1.07M | 2.68M |
Valuation
KPI | 2024 | 2025e | 2026e |
---|---|---|---|
EV / Sales | 0.77x | 0.44x | 0.34x |
EV / EBITDA | 10.25x | 5.96x | 3.58x |
EV / EBIT | (122.59x) | 16.90x | 6.15x |
Price / Earnings | (186.82x) | 26.46x | 10.34x |
EV / FCF | 24.36x | 36.22x | 13.42x |
Downloads
Latest Research
Initiation